Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

Executive Summary

Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but the Roche subsidiary’s drug is a year behind competitors from Bristol-Myers and Merck in NSCLC with seven Phase III trials under way to expand its reach in lung cancer.

Advertisement

Related Content

Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Cautious Roche Stresses: 'It's Not Only About APHINITY'
US Approvals Analysis: Stroke Device, IVDs Highlight October FDA Actions
PD-1 Deep Dive: Lung Cancer Market Braced For Change
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Roche Raises IO Credentials On Tecentriq Lung Cancer Data
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda
For Roche Immuno-Oncology, It’s Steady As She Goes
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel